Immune checkpoint inhibitors plus VEGF tyrosine kinase inhibitors as second-line or later therapy for patients with extensive stage small cell lung cancer

被引：0

作者：

Yan, N. ^{[1
]}

Guo, S. X. ^{[1
]}

Li, M. J. ^{[1
]}

Huang, S. Y. ^{[1
]}

Guo, Q. Q. ^{[1
]}

Geng, D. ^{[1
]}

Zhang, H. X. ^{[1
]}

Li, X. ^{[2
]}

机构：

[1] Zhengzhou Sch Med, Affiliate Hosp 1, Oncol Dept, Zhengzhou, Peoples R China

[2] Zhengzhou Univ, Affiliated Hosp 1, Med Oncol, Zhengzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.243

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1659P

引用

页码：S1168 / S1168

页数：1

共 50 条

[1] Immune checkpoint inhibitors in extensive-stage small cell lung cancer
Zhang, Tongmei
JOURNAL OF THE NATIONAL CANCER CENTER, 2022, 2 (03): : 130 - 131
[2] Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer
Ying, Xixi
Shi, Zheng
Shao, Rongjun
You, Guangxian
Song, Zhengbo
NEOPLASMA, 2024, 71 (03) : 297 - 305
[3] Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma
Fillon, Mike
CA-A CANCER JOURNAL FOR CLINICIANS, 2018, 68 (03) : 178 - 179
[4] Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
Passaro, Antonio
Cortesi, Enrico
de Marinis, Filippo
EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1587 - 1597
[5] FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer
Malinou, Justin Nathaniel
Mehta, Gautam
Vellanki, Paz J.
Larkins, Erin A.
Kluetz, Paul Gustav
Singh, Harpreet
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment
Bianco, Andrea
D'Agnano, Vito
Matera, Maria Gabriella
Della Gravara, Luigi
Perrotta, Fabio
Rocco, Danilo
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (11) : 1415 - 1425
[7] Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience
Caristi, N.
Franchina, T.
Proto, C.
Chiofalo, G.
Toscano, G.
Scimone, A.
Zanghi, M.
Berenato, R.
Briguglio, R.
Denaro, N.
Noto, L.
Adamo, V.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[8] Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
Zhou, Fei
Zhao, Wencheng
Gong, Xiaomei
Ren, Shengxiang
Su, Chunxia
Jiang, Tao
Zhou, Caicun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[9] Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
Khaddour, Karam
Gomez-Perez, Sandra L.
Jain, Nikita
Patel, Jyoti D.
Boumber, Yanis
FRONTIERS IN ONCOLOGY, 2020, 10
[10] Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non-Small Cell Lung Cancer A Multicenter, Retrospective Study
Roh, Jiyeon
Eom, Jung Seop
Lee, Min Ki
Kim, Jehun
Jang, Taewon
Yoon, Seong Hoon
Son, Choon-Hee
Lee, Hyun-Kyung
Kim, Hyun-Kuk
Lee, Shin Yup
Shin, Kyeong Choel
Kim, Mi-Hyun
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (07): : 356 - 360

← 1 2 3 4 5 →